Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2550]

Genomic study of 6000 NCI-MATCH cancer patients leads to new clinical trial benchmarks

Genomic study of 6000 NCI-MATCH cancer patients leads to new clinical trial benchmarks

FDA Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma

FDA Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma

Potential drug treatment for particular type of lung-cancer

Potential drug treatment for particular type of lung-cancer

NRXN1 as a novel potential target for small cell lung cancer

NRXN1 as a novel potential target for small cell lung cancer

Cancer cells use nerve-cell tricks to spread from one organ to the next

Cancer cells use nerve-cell tricks to spread from one organ to the next

New vulnerability found in lung squamous cancer may facilitate drug targeting

New vulnerability found in lung squamous cancer may facilitate drug targeting

ESMO 2020: Amivantamab with lazertinib in patients with EGFR-mutated non-small cell lung cancer

ESMO 2020: Amivantamab with lazertinib in patients with EGFR-mutated non-small cell lung cancer

ESMO 2020: No benefit for post-operative radiotherapy in non-small-cell lung cancer

ESMO 2020: No benefit for post-operative radiotherapy in non-small-cell lung cancer

ESMO 2020: KRAS inhibitor sotorasib appears safe, achieves durable clinical benefit in early trial

ESMO 2020: KRAS inhibitor sotorasib appears safe, achieves durable clinical benefit in early trial

New model predicts oesophageal cancer eight years early for half of all patients

New model predicts oesophageal cancer eight years early for half of all patients

More from ecancer